Xponance Inc. Buys New Position in Astera Labs, Inc. (NASDAQ:ALAB)

Xponance Inc. acquired a new stake in Astera Labs, Inc. (NASDAQ:ALAB - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 5,223 shares of the company's stock, valued at approximately $692,000.

A number of other institutional investors also recently made changes to their positions in the business. Steward Partners Investment Advisory LLC grew its holdings in Astera Labs by 99.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 199 shares of the company's stock worth $26,000 after acquiring an additional 99 shares during the last quarter. Kestra Investment Management LLC bought a new stake in shares of Astera Labs in the fourth quarter worth about $28,000. GAMMA Investing LLC raised its position in Astera Labs by 78.3% during the 4th quarter. GAMMA Investing LLC now owns 510 shares of the company's stock valued at $68,000 after purchasing an additional 224 shares during the last quarter. CIBC Asset Management Inc raised its position in Astera Labs by 5.2% during the 4th quarter. CIBC Asset Management Inc now owns 4,757 shares of the company's stock valued at $630,000 after purchasing an additional 237 shares during the last quarter. Finally, Geneos Wealth Management Inc. purchased a new stake in Astera Labs in the 4th quarter worth approximately $36,000. Hedge funds and other institutional investors own 60.47% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Barclays raised their price target on Astera Labs from $87.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. Northland Securities raised shares of Astera Labs from a "market perform" rating to an "outperform" rating and set a $120.00 target price for the company in a research report on Tuesday, January 28th. Morgan Stanley reduced their price target on shares of Astera Labs from $142.00 to $114.00 and set an "equal weight" rating on the stock in a research report on Tuesday, January 28th. Needham & Company LLC reissued a "buy" rating and issued a $140.00 price target on shares of Astera Labs in a research note on Tuesday, February 11th. Finally, Northland Capmk upgraded Astera Labs from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, January 28th. One equities research analyst has rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $112.77.

Remove Ads

Astera Labs Stock Performance

Shares of ALAB traded down $2.01 during trading hours on Friday, hitting $60.78. The company had a trading volume of 3,132,437 shares, compared to its average volume of 3,661,674. Astera Labs, Inc. has a 52-week low of $36.22 and a 52-week high of $147.39. The firm has a fifty day moving average price of $86.45 and a 200-day moving average price of $89.68. The stock has a market capitalization of $9.86 billion and a price-to-earnings ratio of -35.13.

Astera Labs (NASDAQ:ALAB - Get Free Report) last posted its earnings results on Monday, February 10th. The company reported $0.10 EPS for the quarter, missing analysts' consensus estimates of $0.26 by ($0.16). Astera Labs had a negative return on equity of 10.40% and a negative net margin of 21.05%. Research analysts anticipate that Astera Labs, Inc. will post 0.34 earnings per share for the current fiscal year.

Insider Buying and Selling at Astera Labs

In other news, Director Michael E. Hurlston sold 2,500 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $92.08, for a total transaction of $230,200.00. Following the completion of the transaction, the director now directly owns 91,794 shares of the company's stock, valued at $8,452,391.52. The trade was a 2.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Philip Mazzara sold 7,536 shares of Astera Labs stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $92.07, for a total transaction of $693,839.52. Following the completion of the sale, the general counsel now directly owns 241,209 shares of the company's stock, valued at approximately $22,208,112.63. This trade represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 570,990 shares of company stock worth $50,242,702.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.